|
Methyl aminolevulinate (MAL) is a drug used as a sensitizer in photodynamic therapy. It is a prodrug that is metabolized to protoporphyrin IX. It is marketed as Metvix. Metvix cream is applied topically and some time later the skin is illuminated with a proprietary red light (630 nm) source (medical lamp 'Aktilite') to activate the photosensitiser. Metvix is developed by Photocure and Galderma has bought all rights to Metvix.〔http://photocure.com/NEWS/newcontainer/Photocure-divests-Metvix-to-Galderma-for-EUR-51-million/ Photocure divests Metvix to Galderma〕 ==Approvals and indications== Methyl aminolevulinate is approved in New Zealand for treatment of basal cell carcinoma.〔http://dermnetnz.org/procedures/metvix-pdt.html "Methyl aminolevulinate photodynamic therapy (MAL PDT)"〕 It is now approved in many countries and has been used to treat non-melanoma skin cancer (including basal cell carcinoma).〔http://www.medicalnewstoday.com/articles/36953.php "New 5 Year Metvix-PDT Data Demonstrate Long-Term Efficacy & Reliability For NM Skin Cancer Treatment" 2006〕 It has some advantages over Levulan.〔http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_13/ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009 by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T〕 It has been reported as controversial in some quarters, with severe pain allegedly being experienced by some patients. 〔http://www.abc.net.au/news/2013-11-16/concerns-raised-over-side-effects-of-skin-cancer-cream/5096496〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Methyl aminolevulinate」の詳細全文を読む スポンサード リンク
|